Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepacia grows in cystic fibrosis sputum.
BACKGROUND
Bacteria from the Burkholderia cepacia complex (Bcc) are the only group of cystic fibrosis (CF) respiratory pathogens that may cause death by an invasive infection known as cepacia syndrome. Their large genome (> 7000 genes) and multiple pathways encoding the same putative functions make virulence factor identification difficult in these bacteria.


METHODS
A novel microarray was designed to the genome of Burkholderia cenocepacia J2315 and transcriptomics used to identify genes that were differentially regulated when the pathogen was grown in a CF sputum-based infection model. Sputum samples from CF individuals infected with the same B. cenocepacia strain as genome isolate were used, hence, other than a dilution into a minimal growth medium (used as the control condition), no further treatment of the sputum was carried out.


RESULTS
A total of 723 coding sequences were significantly altered, with 287 upregulated and 436 downregulated; the microarray-observed expression was validated by quantitative PCR on five selected genes. B. cenocepacia genes with putative functions in antimicrobial resistance, iron uptake, protection against reactive oxygen and nitrogen species, secretion and motility were among the most altered in sputum. Novel upregulated genes included: a transmembrane ferric reductase (BCAL0270) implicated in iron metabolism, a novel protease (BCAL0849) that may play a role in host tissue destruction, an organic hydroperoxide resistance gene (BCAM2753), an oxidoreductase (BCAL1107) and a nitrite/sulfite reductase (BCAM1676) that may play roles in resistance to the host defenses. The assumptions of growth under iron-depletion and oxidative stress formulated from the microarray data were tested and confirmed by independent growth of B. cenocepacia under each respective environmental condition.


CONCLUSIONS
Overall, our first full transcriptomic analysis of B. cenocepacia demonstrated the pathogen alters expression of over 10% of the 7176 genes within its genome when it grows in CF sputum. Novel genetic pathways involved in responses to antimicrobial resistance, oxidative stress, and iron metabolism were revealed by the microarray analysis. Virulence factors such as the cable pilus and Cenocepacia Pathogenicity Island were unaltered in expression. However, B. cenocepacia sustained or increased expression of motility-associated genes in sputum, maintaining a potentially invasive phenotype associated with cepacia syndrome.
Drevinek
Pavel
P
Cardiff School of Biosciences, Cardiff University, Cardiff, UK. pavel.drevinek@lfmotol.cuni.cz
Holden
Matthew T G
MT
Ge
Zhaoping
Z
Jones
Andrew M
AM
Ketchell
Ian
I
Gill
Ryan T
RT
Mahenthiralingam
Eshwar
E
D000328:Adult; D001426:Bacterial Proteins / Q000235:genetics; D042602:Burkholderia cepacia complex / Q000254:growth & development / Q000502:physiology*; D003550:Cystic Fibrosis; D024881:Drug Resistance, Bacterial; D020869:Gene Expression Profiling; D015964:Gene Expression Regulation, Bacterial; D006801:Humans; D007501:Iron / Q000378:metabolism; D008124:Locomotion; D020411:Oligonucleotide Array Sequence Analysis; D018384:Oxidative Stress; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013183:Sputum / Q000382:microbiology*
D001426:Bacterial Proteins; D007501:Iron
Lancet. 1993 Jul 3;342(8862):15-9
7686239
Antimicrob Agents Chemother. 2004 Apr;48(4):1145-50
15047514
Nat Rev Microbiol. 2004 Oct;2(10):820-32
15378046
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14240-5
15377794
Infect Immun. 1993 Aug;61(8):3157-63
7687582
Infect Immun. 1994 Feb;62(2):596-605
8300217
Mol Microbiol. 1993 Nov;10(3):529-44
7968531
J Bacteriol. 1998 May;180(10):2636-43
9573147
J Bacteriol. 1998 Jun;180(11):2936-42
9603885
Am J Respir Crit Care Med. 1999 Sep;160(3):796-801
10471599
Thorax. 2004 Nov;59(11):948-51
15516469
Nat Rev Microbiol. 2005 Feb;3(2):144-56
15643431
J Med Microbiol. 2005 Jul;54(Pt 7):655-9
15947430
J Bacteriol. 2005 Aug;187(15):5267-77
16030221
Infect Immun. 2005 Aug;73(8):4982-92
16041013
J Clin Microbiol. 2005 Sep;43(9):4665-73
16145124
BMC Genomics. 2006;7:72
16595014
J Biol Chem. 2006 Jun 16;281(24):16256-63
16603772
Infect Immun. 2006 Jul;74(7):4083-93
16790782
BMC Microbiol. 2006;6:66
16857052
Environ Microbiol. 2007 Apr;9(4):1017-34
17359273
Biometals. 2007 Jun;20(3-4):431-52
17295049
Future Microbiol. 2007 Apr;2(2):153-64
17661652
Cell. 2007 Sep 7;130(5):797-810
17803904
FEMS Microbiol Lett. 2007 Nov;276(1):83-92
17937666
J Bacteriol. 2000 Apr;182(8):2077-87
10735848
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1206-12
10764313
Infect Immun. 2000 Dec;68(12):6554-60
11083764
Microbiology. 2001 Jan;147(Pt 1):97-109
11160804
Res Microbiol. 2001 Jan-Feb;152(1):17-26
11281321
Mol Microbiol. 2001 May;40(3):542-54
11359562
Am J Respir Crit Care Med. 2001 Jul 1;164(1):92-6
11435245
FEMS Microbiol Lett. 2001 Aug 21;202(2):157-64
11520608
Clin Infect Dis. 2001 Nov 1;33(9):1469-75
11588691
Infect Immun. 2002 Apr;70(4):1799-806
11895941
J Biol Chem. 2002 Jun 28;277(26):23664-9
11960983
Paediatr Respir Rev. 2002 Sep;3(3):230-5
12376059
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
EMBO J. 2002 Dec 16;21(24):6649-59
12485986
Res Microbiol. 2003 Mar;154(2):91-6
12648723
Microbiology. 2003 Apr;149(Pt 4):961-71
12686638
Microbiology. 2003 Aug;149(Pt 8):2263-71
12904566
Microbiology. 2003 Nov;149(Pt 11):3051-72
14600218
FEMS Microbiol Lett. 2003 Nov 21;228(2):287-97
14638436
Microbiology. 2003 Dec;149(Pt 12):3649-58
14663096
J Clin Invest. 2004 Feb;113(3):464-73
14755343
Infect Immun. 2004 Mar;72(3):1537-47
14977960
Microbiology. 2004 Mar;150(Pt 3):516; discussion 516-8
14993297
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6664-8
15084751